ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/QLD/4575-Birtinya-Sunshine-Coast-University-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
36
trial(s) found.
NCT06921837
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer (
BBI-4182-101
)
anti-CLDN18.2 immune-stimulating antibody conjugate,TLR7/8 agonist
Adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06868199
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours (
LM168-01-101
)
anti-PD-1 monoclonal antibody
unknown drug class
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06742996
Haem
Phase 3
Recruiting
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma (
BGB-11417-302
)
BCL2 inhibitor
BTK inhibitor
placebo
B-cell lymphoma
Mantle cell lymphoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT06497556
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
Krascendo-1
)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT06357533
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (
TROPION-Lung10
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
4215 - Southport - Gold Coast University Hospital (WITHDRAWN)
NCT06356129
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (
GOLSEEK-1
)
CELMoD agent
placebo
Diffuse large B-cell lymphoma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
QLD
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06119581
Advanced
Phase 3
Recruiting
SUNRAY-01
, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
antimetabolite
placebo
Non-small cell lung cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4740 - Mackay - Mackay Base Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06018337
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (
DB-1303-O-3002
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06007482
Advanced
Phase 1
Recruiting
An Open-Label, Multicenter, First-in-Human, Phase 1 Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors (
ES009-1001
)
anti-LILRB2 monoclonal antibody
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2217 - Kogarah - St George Private Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT05923008
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicenter, Open-label Study of IBI130 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (
CIBI130A101
)
anti-Trop2 antibody-drug conjugate
anti-Trop2 monoclonal antibody
Solid tumour
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT05914116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors (
DB-1311-O-1001
)
anti-B7H3 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2228 - Miranda - Southside Cancer Care Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05886868
Advanced
Phase 1
Recruiting
A Phase I, International, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0020 as A Single Agent in Patients With Advanced Solid Tumors (
BL0020-101
)
unknown drug class
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NA
NA
NCT05774951
Curative
Phase 3
Recruiting
CAMBRIA-1
: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
selective estrogen receptor degrader
selective estrogen receptor modulator
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2485 - Tweed Heads - The Tweed Hospital
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (WITHDRAWN)
NCT05519085
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-1
cereblon E3 ligase modulator
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.9016 - Dunedin - Dunedin Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (WITHDRAWN)
NCT05393791
Advanced
Phase 2
Recruiting
ANZadapt
: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05243797
Haem
Phase 3
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation -
MajesTEC-4
bispecific T-cell engager,BCMA-targeting
immunomodulatory imide drug
Multiple myeloma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4575 - Birtinya - Sunshine Coast University Hospital
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05199753
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours (
LM108-01-101
)
anti-CCR8 monoclonal antibody
Solid tumour
NA
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
NCT04975997
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) (
EXCALIBER-RRMM
)
CELMoD agent
anti-CD38 monoclonal antibody
glucocorticoid
proteasome inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
ACT
2605 - Garran - The Canberra Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6150 - Murdoch - Fiona Stanley Hospital
NCT04964518
Haem
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS (
APG2575AU101
)
BCL2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Solid tumour
VIC
3066 - Epping - Northern Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04789096
Advanced
Phase 2
Recruiting
A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients with Pre-treated Advanced HER2-positive Breast Cancer (
TUGETHER
)
ERBB2 inhibitor,third generation
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Breast cancer
HER2-positive breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
ACTRN12623000956606
Advanced
Phase 1
Recruiting
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies (
Australia
)
dual IDO/TDO inhibitor
Solid tumour
NSW
2228 - Miranda - Southside Cancer Care Centre
VIC
3066 - Epping - Northern Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12622001366741
Haem
Phase 2
Recruiting
Investigating the efficacy of Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The
RIDDLE-M-X
trial
XPO1 inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2640 - Albury - Border Medical Oncology Research Unit
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12622000973718
Advanced
Phase 2
Recruiting
SHERLOCK
: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
anti-VEGF monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2086 - Frenchs Forest - Northern Beaches Hospital
2170 - Liverpool - Liverpool Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12620000757910
Curative
Not Applicable
Recruiting
Functional imaging-guided radiotherapy dose escalation in rectal adenocarcinoma: a feasibility study (
FIGURE-rectal
)
radiotherapy
Rectal adenocarcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12619001199101
Haem
Phase 1 / Phase 2
Recruiting
Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the
FRAIL-M
study
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NA
2025 - Papatoetoe - Middlemore Hospital
NSW
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4350 - Toowoomba - Toowoomba Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12618000977279
Advanced
Phase 1
Not yet recruiting
A Phase 1 Study on the safety and maximum tolerated dose of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein, in Patients with Advanced Solid Tumors (
HLX20-001
)
anti-PD-1 monoclonal antibody
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06295809
Curative
Phase 2 / Phase 3
Active not recruiting
A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant V940 (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007). (
V940-007
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Carcinoma
Skin cancer
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06267001
Curative
Phase 3
Active not recruiting
A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (
SKYSCRAPER-15
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
placebo
Non-small cell lung cancer
VIC
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT05805501
Advanced
Phase 2
paused
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (
BO43936
)
KIT inhibitor,ATP-competitive
VEGFR/PDGFR inhibitor
Clear cell renal cell carcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT05625399
Advanced
Phase 3
Not recruiting
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma (
RELATIVITY-127
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2650 - Wagga Wagga - Riverina Cancer Care Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3844 - Traralgon - Latrobe Regional Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05558696
Haem
Phase 2
Active not recruiting
A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bomedemstat in Patients With Polycythemia Vera (PV) (
3543-004
)
LSD1 inhibitor
Polycythemia vera
VIC
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT05348577
Advanced
Phase 3
Active not recruiting
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (
CAPItello280
)
pan-AKT inhibitor
placebo
taxane
Prostate cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
QLD
4020 - Redcliffe - Redcliffe Hospital
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT03280667
Advanced
Phase 2
Unknown
Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma: a Phase II Trial (ANZUP 1601) (
KEYPAD
)
anti-PD-1 monoclonal antibody
anti-RANK L monoclonal antibody
Clear cell renal cell carcinoma
Kidney cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2086 - Frenchs Forest - Northern Beaches Hospital
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT03177239
Advanced
Phase 2
Status unknown
A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602). (
UNISoN
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Carcinoma
Chromophobe renal cell carcinoma
Clear cell renal cell carcinoma
Sarcomatoid renal cell carcinoma
Type 1 papillary renal cell carcinoma
Type 2 papillary renal cell carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2086 - Frenchs Forest - Northern Beaches Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT02773524
Advanced
Phase 3
Unknown
A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) (
INTEGRATEIIa
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
placebo
Gastroesophageal cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Newcastle Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (24)
Active not recruiting (4)
Not yet recruiting (3)
Unknown (2)
paused (1)
Not recruiting (1)
Status unknown (1)
Recruitment Country and State
QLD (36)
NSW (30)
VIC (28)
WA (15)
SA (15)
NZ (7)
TAS (5)
NT (3)
ACT (3)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (7)
Phase 2 (8)
Phase 2 / Phase 3 (1)
Phase 3 (15)
Trial Type
Advanced (22)
Haem (10)
Curative (4)
Cancer Therapy Class
PD-1/PD-L1
31%
PD-1
28%
cereblon
17%
proteasome
11%
KRAS
8%
KRAS G12C
8%
TIGIT
8%
BCL2
6%
HRAS G12C
6%
NRAS G12C
6%
Trop2
6%
CD20
6%
ERBB2
6%
KIT
6%
LAG3
6%
PDGFR
6%
VEGFR
6%
CLDN18.2
3%
BTK
3%
LILRB2
3%
B7H3
3%
ER
3%
oestrogen axis
3%
AR
3%
CYP17A1
3%
androgen axis
3%
BCMA
3%
CCR8
3%
CD38
3%
DNA methyltransferase
3%
CD79b
3%
IDO
3%
TDO
3%
XPO1
3%
VEGF
3%
PD-L1
3%
LSD1
3%
AKT
3%
RANK L
3%
CTLA4
3%
FGFR
3%
FGFR1
3%
FGFR1/2/3
3%
FGFR2
3%
FGFR3
3%
FGFR4
3%
RET
3%
Facility
4575 - Birtinya - Sunshine Coast University Hospital (36)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (10)
3168 - Clayton - Monash Medical Centre (9)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (9)
2139 - Concord - Concord Repatriation General Hospital (8)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (8)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (7)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (7)
2050 - Camperdown - Chris O'Brien Lifehouse (7)
3004 - Melbourne, Southbank - Alfred Health (7)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (6)
3128 - Box Hill - Box Hill Hospital - Eastern Health (6)
4215 - Southport - Gold Coast University Hospital (6)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (6)
2170 - Liverpool - Liverpool Hospital (5)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (5)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (5)
3021 - St Albans - Western Health - Sunshine Hospital (5)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (5)
2031 - Randwick - Prince of Wales Hospital (5)
2217 - Kogarah - St George Hospital (5)
6150 - Murdoch - Fiona Stanley Hospital (5)
5042 - Bedford Park - Flinders Medical Centre (5)
3066 - Epping - Northern Hospital (5)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
NZ.9016 - Dunedin - Dunedin Hospital (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
3065 - Fitzroy - St Vincent's Hospital Melbourne (4)
2109 - North Ryde - Macquarie University Hospital (4)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (4)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (4)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (4)
7000 - Hobart - Royal Hobart Hospital (4)
2500 - Wollongong - Wollongong Hospital (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (3)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (3)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (3)
2031 - Randwick - Scientia Clinical Research Ltd (3)
2640 - Albury - Albury Wodonga Regional Cancer Centre (3)
2605 - Garran - The Canberra Hospital (3)
6000 - Perth - Royal Perth Hospital (3)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (3)
2640 - Albury - Border Medical Oncology Research Unit (3)
2086 - Frenchs Forest - Northern Beaches Hospital (3)
5011 - Woodville South - The Queen Elizabeth Hospital (3)
6009 - Nedlands - Linear Clinical Research (2)
6009 - Nedlands - One Clinical Research (2)
NZ.0622 - Takapuna - North Shore Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
2228 - Miranda - Southside Cancer Care Centre (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
2485 - Tweed Heads - The Tweed Hospital (2)
2076 - Wahroonga - Sydney Adventist Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (2)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (2)
6005 - West Perth - Perth Blood Institute (1)
6168 - Cooloongup - Rockingham Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4740 - Mackay - Mackay Base Hospital (1)
2217 - Kogarah - St George Private Hospital (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
NA
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (1)
4217 - Benowa - Pindara Private Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
2487 - Cudgen - Tweed Valley Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
2025 - Papatoetoe - Middlemore Hospital
3011 - Footscray - Footscray Hospital (1)
4350 - Toowoomba - Toowoomba Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
2650 - Wagga Wagga - Riverina Cancer Care Centre (1)
4020 - Redcliffe - Redcliffe Hospital (1)
2305 - New Lambton Heights - Newcastle Private Hospital (1)
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Thoracic cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Multiple myeloma
Plasma cell disorder
Urogenital cancer
Carcinoma
Gastrointestinal cancer
B-cell lymphoma
B-cell malignancy
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Breast cancer
Clear cell renal cell carcinoma
Kidney cancer
Gastroesophageal cancer
Upper gastrointestinal cancer
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Male genital cancers
Prostate cancer
Adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Mantle cell lymphoma
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Breast adenocarcinoma
HER2-positive breast cancer
Non-squamous non-small-cell lung cancer
Colorectal adenocarcinoma
Colorectal cancer
Lower gastrointestinal cancer
Rectal adenocarcinoma
Skin cancer
Melanoma
Myeloproliferative neoplasm
Polycythemia vera
Chromophobe renal cell carcinoma
Non-clear cell renal cell carcinoma
Papillary renal cell carcinoma
Sarcomatoid renal cell carcinoma
Type 1 papillary renal cell carcinoma
Type 2 papillary renal cell carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy